VectivBio Holding a clinical-stage biopharmaceutical company, has announced a combined gross proceeds from public offering and private sale of USD 50 million. On one side, the company has announced the pricing of a follow-on public offering
Search Results for: Homburger
Julius Baer Group has placed a perpetual non-cumulative Additional Tier 1 (AT1) securities in a USD 400 million transaction with private banks and institutional investors in Asia and Europe. The transaction will help to optimise Julius Baer
HIAG Immobilien Holding has placed a fixed-interest bond on the Swiss capital market in the amount of CHF 150 million with a coupon of 1.77% and a term of 4 years and 5 months, maturing as of 30 October 2026. The
Kering completed the sale of Sowind Group, which owns the Swiss watch manufacturers Girard-Perregaux and Ulysse Nardin, to Sowind’s management. The luxury Group has supported the two Houses in their development, strengthened their positioning
Credit Suisse has successfully completed its issuance of €1 billion aggregate principal amount of 2.125% senior notes due 2024 and €750 million aggregate principal amount of floating rate senior notes due 2024. The bonds were issued under Credit Suisse’s
David Borer has joined the banking & finance team of Walder Wyss as a new partner in the Zurich office. Borer is a corporate finance specialist with a focus on complex national and international financing
DSM and Firmenich have entered into a business combination agreement to establish the leading creation and innovation partner in nutrition, beauty and well-being. The Dutch specialty chemicals maker has said that this merge with Swiss
Pwc has completed the sale of its global mobility services business, Vialto Partners, to Clayton, Dubilier & Rice (CD&R). Vialto Partners had previously operated within the PwC network as the Global Mobility Services
Sonova Holding, providers of hearing aid solutions, has completed the placement of CHF 450 million Bonds governed by Swiss law. Application will be made for the Bonds to be listed on the SIX Swiss Exchange. The
CDR-Life, a Swiss biotechnology company pioneering a new and differentiated class of highly tumor-specific immune-oncology therapeutics, has completed its Series A financing raising USD 76 million. The round was led by Jeito Capital and RA Capital
